Cabergoline Stimulates Synthesis and Secretion of Nerve Growth Factor, Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor by Mouse Astrocytes in Primary Culture

Neuroprotection is the primary concern in patients with newly diagnosed Parkinson’s disease. The D 2 /weak D 1 dopamine agonist cabergoline elicits neuroprotection by antioxidation and scavenging free radicals, and may protect neurons by up-regulating endogenous neurotrophic factors synthesis in the brain. In primary cultured mouse astrocytes, cabergoline 37 µmol/l immediately elevated concentrations of nerve growth factor, brain-derived neurotrophic factor, and glial cell line-derived neurotrophic factor (GDNF) in culture medium, reaching 9.9-, 2.6- and 30-fold, respectively, of control levels at 16 h. Relative mRNA levels were 3.0-, 1.5- and 1.9-fold, respectively, of controls at 3 h. These effects may be mediated partly by the dopamine D 2 receptor. Cabergoline may be a good candidate for an inducer of GDNF, which may have neuroprotective and neurorestorative properties in dopaminergic nigral neurons.